PEPTIDE: DSIP (Delta Sleep-Inducing Peptide)
DSIP was named for inducing delta sleep, but independent labs failed to replicate that in humans, no one has found its receptor or gene, and its best human stress trial found zero effect. Fascinating biology, unproven clinically.
Pinned Admin
DSIP was named for inducing delta sleep, but independent labs failed to replicate that in humans, no one has found its receptor or gene, and its best human stress trial found zero effect. Fascinating biology, unproven clinically.
1.The Delta Sleep Riddle
In 1977, a team at the University of Basel, led by Schoenenberger and Monnier, isolated a nonapeptide from the cerebral venous blood of rabbits given low-frequency electrical stimulation. It appeared to induce the slow-wave brain activity of deep rest, so they named it Delta Sleep-Inducing Peptide (DSIP).
Half a century later, DSIP is still one of the least understood substances in biotech, often called an unresolved riddle: a molecule that produces real physiological effects while defying classical pharmacology. The honest takeaways below challenge the very name of the substance.
DSIP has no identified receptor, no identified gene, and a name its own human sleep data does not support. Most evidence is decades old. Read the safety and claims sections before drawing conclusions.
2.The Name Is a Misnomer
The name suggests a direct sedative, like a hypnotic. Modern researchers consider that a misnomer. Evidence for DSIP as a primary sleep-inducing agent in humans is inconsistent and lacks the reproducibility needed for clinical validation.
Early 1980s trials suggested it could increase total sleep time, but independent labs, including those of Obal, Kovalzon, and Borbely, failed to replicate the effect. In several controlled settings the peptide paradoxically increased wakefulness or impaired sleep architecture. It does not behave like a CNS depressant; it looks more like a regulator that only shows effect when the sleep-wake cycle is already disturbed.
“The name 'Delta Sleep-Inducing Peptide' is widely considered a misnomer that significantly oversells the human sleep data.”
3.The Ghost Mechanism
In classical pharmacology a drug acts by binding a defined receptor. DSIP is an anomaly: after 50 years, no single well-characterised membrane receptor and no dedicated gene have been identified. It behaves less like a standard signal and more like a metamodulator or programming factor.
Met-enkephalin secretagogue: DSIP triggers calcium-dependent, tetrodotoxin-insensitive release of the endogenous opioid Met-enkephalin from nerve endings, rather than binding opioid receptors directly.
System stabiliser: it shifts the functional state of GABAergic, NMDA-glutamatergic, and alpha-1-adrenergic systems together, toward homeostatic balance rather than forcing one pathway.
This is also why a half-life of roughly 7 to 8 minutes can produce effects that take ~130 minutes to emerge and persist for days, a paradox the field still cannot fully explain.
Explore This Protocol
Stay Ahead of the Research
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.